NCT00656448View on ClinicalTrials.gov

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Acute Myelogenous LeukemiaMyelodysplastic SyndromeLeukemia
Interventions
DRUG

Procrit

40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.

Trial Locations (1)

77030

The University of Texas M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER